Christian Roux - Concepedia

Author

Christian Roux

Also Known As

C Roux, C. ROUX, C. Roux, C.H. Roux, CHRISTIAN ROUX, Christian ROUX, Christian Roux, Damien Loeuille, Eisel, T., F. Jakob

641

Publications

27.3K

Citations

H-Index

196

Concepts

All Affiliations

Hôpital Cochin Université Paris Cité Délégation Paris 5 Inserm Assistance Publique – Hôpitaux de Paris

About

Christian Roux is an author at Hôpital Cochin specializing in medicine, osteoporosis, and orthopaedics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	56	122	11.8K
2	Health Sciences	21	33	2K
3	Engineering	13	15	760
4	Education	1	1	42
5	Management	1	1	23

Christian Roux

216

Publications

20.9K

Citations

H-Index

Page 1

	Year	Citations
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis Pierre J. Meunier, Christian Roux, Ego Seeman, New England Journal of Medicine	2004	1.6K
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis Jean‐Yves Reginster, H. W. Minne, O. H. Sørensen, Osteoporosis International Bone HealthEstablished Postmenopausal OsteoporosisGynecologyVertebral FracturesMedicine	2000	1.6K
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi, The Lancet Diabetes & Endocrinology Bone DiseaseDenosumab TreatmentBone HealthPhase 3Osteopathy	2017	916
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension Steven R. Cummings, Serge Ferrari, Richard Eastell, Journal of Bone and Mineral Research	2017	677
Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW Juliet Compston, Nelson B. Watts, Roland Chapurlat, The American Journal of Medicine ObesityBone DiseaseBone HealthObesity ManagementGynecology	2011	544
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial David M. Reid, Jean‐Pierre Devogelaer, Kenneth G. Saag, The Lancet Bone DiseaseZoledronic AcidBone HealthGlucocorticoid-induced OsteoporosisMedicine	2009	525
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy David L. Kendler, Christian Roux, Claude Laurent Benhamou, Journal of Bone and Mineral Research Bone DiseaseAdverse EventsBone HealthPharmacologyBone Mineral Density	2009	447
Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis Dan Mellström, O. H. Sørensen, Stefan Goemaere, Calcified Tissue International Bone DiseaseBone HealthMedicineGynecologyMenopause	2004	349
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension Socrates E. Papapoulos, Roland Chapurlat, Cesar Libanati, Journal of Bone and Mineral Research	2011	340
Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density Henry G. Bone, Michael R. McClung, Christian Roux, Journal of Bone and Mineral Research GynecologyCysteine ProteasePharmacotherapyLow Bone DensityOrthopaedic Surgery	2009	330

Page 1